RBP4 inhibitor 1 (compound 43b) is an orally active and potent inhibitor of retinol-binding protein 4 (RBP4), exhibiting IC50 values of 28 nM and 110 nM for human and mouse RBP4, respectively. It effectively reduces blood RBP4 levels in mice, providing a long-lasting effect [1].
SNU-BP is an agonist of PPAR-gamma, inhibiting lipopolysaccharide (LPS)-induced NO production and pro-inflammatory cytokines. SNU-BP potentiates interleukin-4-induced arginase-1 expression, and promotes microglial polarization toward an M2 anti-inflammatory phenotype.